Press Releases
Information updates and press releases issued by Deep Genomics

DEEP GENOMICS APPOINTS JAMES DOWLING AS CHIEF MEDICAL OFFICER

June 24, 2019

James Dowling, M.D., Ph.D. is joining the leadership team at Deep Genomics as Chief Medical Officer. Jim's understanding of patient needs combined with expertise on rare disease biology is crucial to guide the design of AI systems to accelerate clinical development. 

Toronto, Ontario – June 24, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that James Dowling, M.D., Ph.D., is joining the team as Chief Medical Officer, effective today.

“Deep Genomics has identified therapeutic opportunities addressing hundreds of ...

DEEP GENOMICS EXPANDS LABORATORY, APPOINTS JOHAN FRANSSON AS HEAD OF PRECLINICAL RESEARCH

June 18, 2019

To support preclinical research and address the growing number of programs in our pipeline, Deep Genomics has expanded our experimental facility and appointed Johan Fransson.

TORONTO, Ontario, Canada – June 18, 2019. Deep Genomics, the leading AI therapeutics company, announced today that the output of its discovery pipeline has quadrupled in the past year and that it has appointed Johan Fransson, Ph.D. as Head of Preclinical Research, effective immediately.

“We ...

Discovering Therapies for Neuromuscular Disorders

April 10, 2018

Deep Genomics to collaborate with Wave Life Sciences to discover novel therapies for genetic neuromuscular disorders

CAMBRIDGE, Mass. U.S.A. and TORONTO, Ontario, Canada, April 10, 2018 - Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., the leading AI therapeutics company that is building a ...

Taking on Metabolic & Neurodegenerative Disorders

March 26, 2018

Deep Genomics to identify oligonucleotide candidates for treating genetically defined metabolic and neurodegenerative disorders

For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders.


TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the leading AI therapeutics company that has built a platform using ...

$13M Invested in AI Platform for Genetic Medicines

September 25, 2017

Equity investment by Khosla Ventures, True Ventures and Bloomberg Beta will be used to direct platform to drug discovery

AI platform to unlock new classes of anti-sense oligonucleotide therapies.


TORONTO, Ontario, Canada, September 25, 2017 - Deep Genomics, the leading AI therapeutics company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by ...

Canada Tries to Turn Its A.I. Ideas Into Dollars

April 9, 2017

Steve Lohr, New York Times

Brendan Frey, the chief executive, studied under Mr. Hinton at the University of Toronto, and he has spent years on research that combines deep-learning A.I. and cell biology. When he hires software engineers, he asks them to make multiyear commitments. “There are a lot ...

How artificial intelligence could transform the medical world

May 9, 2016

Kate Allen, Toronto Star

Artificial intelligence is already powering your Google searches, your Netflix recommendations, and your smartphone’s virtual assistant. It is playing humans at complex, intuitive games like Go, and it is beating them. Now, researchers say, they want AI to power your doctor’s diagnoses, your ...

New company plans to revolutionize genomic medicine with deep learning

July 26, 2015

Richard Moss, New Atlas

Deep learning has already had a huge impact on computer vision and speech recognition, and it's making inroads in areas as computer-unfriendly as cooking. Now a new startup led by University of Toronto professor Brendan Frey wants to cause similar reverberations in genomic medicine ...